Cancer clinical trials in the region Île-de-France

787 currently recruiting clinical trials
Region Île-de-France
Phase 1 / Phase 2 Lymphoma #NCT06137144
Required histologic types
Hodgkin lymphoma
Required number of previous lines of therapy
1 2 3 or more
Excluded previous treatments
Systemic Treatment-Naive
4 recruiting sites
AstraZeneca
Phase 1 / Phase 2 Breast cancer Lung cancer Colon cancer Rectal cancer Head and neck cancer #NCT06657222
Required histologic types
SCLC (Small Cell Lung Cancer) NSCLC (Non-Small Cell Lung Cancer)
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Negative
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Tubulis GmbH
Phase 1 / Phase 2 Lung cancer #NCT06362252 #2023-509629-36-00
Required histologic types
SCLC (Small Cell Lung Cancer)
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
8 recruiting sites
Daiichi Sankyo
Phase 1 / Phase 2 Lung cancer #NCT07227298 #2025-523526-40-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK BRAF EGFR MET NTRK-1/2/3 ROS-1
4 recruiting sites
Pfizer
Phase 1 / Phase 2 Kidney cancer #NCT05287945
Required histologic types
Clear cell carcinoma Papillary carcinoma
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Oncorena AB
Phase 1 / Phase 2 Lung cancer #NCT06567015 #2023-510203-21-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Lung cancer #NCT06567015 #2023-510203-21-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
EGFR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Laboratoires Pierre Fabre
Phase 1 / Phase 2 Lung cancer #NCT05751798 #2024-514826-22-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required disease stage
Metastatic
Required PDL1 statuses
PDL1 Positive (>= 50%)
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
ALK EGFR ROS-1
Excluded previous treatments at localized stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
4 recruiting sites
OSE Immunotherapeutics
Phase 1 / Phase 2 Head and neck cancer #NCT06016920 #2022-503055-26-00
Required histologic types
Oropharynx
Required histologic sub types
Squamous cell carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required HPV statuses
HPV Positive
Required CPS scores
CPS Positive (1 <= X < 20) CPS Positive (X >= 20)
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Car-T Bispecific T-cell engager antibodies
2 recruiting sites
Nykode Therapeutics ASA
Phase 1 / Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Acute leukemia Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Skin cancer #NCT07213830 #2025-522184-15-00
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required number of previous lines of therapy
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Immunotherapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
1 recruiting site
Ipsen